Cargando…

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies

Bispecific T cell engagers (BiTEs) are an innovative class of immunotherapeutics that redirect T cells to tumor surface antigens. While efficacious against certain hematological malignancies, limited bioavailability and severe toxicities have so far hampered broader clinical application, especially...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heidbuechel, Johannes P. W., Engeland, Christine E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8052795/ https://www.ncbi.nlm.nih.gov/pubmed/33863363 http://dx.doi.org/10.1186/s13045-021-01075-5

Ejemplares similares

Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma
por: Saha, Dipongkor, et al.
Publicado: (2020)

Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
por: Jafari, Mahdie, et al.
Publicado: (2022)

Herpes Simplex Virus Oncolytic Immunovirotherapy: The Blossoming Branch of Multimodal Therapy
por: Menotti, Laura, et al.
Publicado: (2020)

Oncolytic adenoviruses: A potent form of tumor immunovirotherapy
por: Cerullo, Vincenzo, et al.
Publicado: (2012)

In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
por: Jahan, Nusrat, et al.
Publicado: (2021)

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV(POS) Cancers
por: Suksanpaisan, Lukkana, et al.
Publicado: (2018)

Immunovirotherapy for glioblastoma
por: Ning, Jianfang, et al.
Publicado: (2014)

Oncolytic immunovirotherapy for high-grade gliomas: A novel and an evolving therapeutic option
por: Asija, Sweety, et al.
Publicado: (2023)

A vector-encoded bispecific killer engager to harness virus-activated NK cells as anti-tumor effectors
por: Floerchinger, Alessia, et al.
Publicado: (2023)

Immunovirotherapy for the treatment of glioblastoma
por: Cheema, Tooba A, et al.
Publicado: (2014)

Modular network mechanism of CCN1-associated resistance to HSV-1-derived oncolytic immunovirotherapies for glioblastomas
por: Monie, Dileep D., et al.
Publicado: (2021)

Measles Virus as an Oncolytic Immunotherapy
por: Engeland, Christine E., et al.
Publicado: (2021)

EPCT-22 SAFETY AND EFFICACY OF INTRAVENTRICULAR IMMUNOVIROTHERAPY WITH ONCOLYTIC HSV-1 G207 FOR TREATMENT OF LEPTOMENINGEAL DISEASE
por: Kang, Kyung-Don, et al.
Publicado: (2021)

Oncolytic Measles Virus Encoding MicroRNA for Targeted RNA Interference †
por: Anker, Sophie C., et al.
Publicado: (2023)

Immunovirotherapy Based on Recombinant Vesicular Stomatitis Virus: Where Are We?
por: Zhang, Yuguo, et al.
Publicado: (2022)

Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer
por: Liu, Shiyu, et al.
Publicado: (2023)

Intraventricular immunovirotherapy; a translational step forward
por: Bernstock, Joshua D., et al.
Publicado: (2023)

Oncolytic vaccinia virus expressing a bispecific T-cell engager enhances immune responses in EpCAM positive solid tumors
por: Wei, Min, et al.
Publicado: (2022)

Blueprint for engagement: authentic leadership
por: Hollis, Norma T
Publicado: (2018)

Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager
por: de Sostoa, Jana, et al.
Publicado: (2019)

Fighting Cancer with Mathematics and Viruses
por: Santiago, Daniel N., et al.
Publicado: (2017)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors
por: Basnet, Saru, et al.
Publicado: (2022)

Advances in oncolytic virotherapy
por: Russell, Stephen J., et al.
Publicado: (2022)

Oncolytic adenovirus expressing bispecific antibody targets T‐cell cytotoxicity in cancer biopsies
por: Freedman, Joshua D, et al.
Publicado: (2017)

Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy
por: Ravirala, Divya, et al.
Publicado: (2021)

Safety study supports clinical development of immunotherapeutic oncolytic measles vaccine
por: Engeland, Christine E.
Publicado: (2022)

Immunovirotherapy for Pediatric Solid Tumors: A Promising Treatment That is Becoming a Reality
por: de la Nava, Daniel, et al.
Publicado: (2022)

Systemic administration of mesenchymal stem cells loaded with a novel oncolytic adenovirus carrying a bispecific T cell engager against hepatocellular carcinoma
por: Yuan, Xiangfei, et al.
Publicado: (2023)

The landscape of bispecific T cell engager in cancer treatment
por: Zhou, Shujie, et al.
Publicado: (2021)

Bispecific Antibody-Based Immune-Cell Engagers and Their Emerging Therapeutic Targets in Cancer Immunotherapy
por: Shin, Ha Gyeong, et al.
Publicado: (2022)

Current strategies in engaging oncolytic viruses with antitumor immunity
por: Boagni, Drew Ashton, et al.
Publicado: (2021)

For whom the T cells troll? Bispecific T-cell engagers in glioblastoma
por: Singh, Kirit, et al.
Publicado: (2021)

Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory
por: Veinalde, Rūta, et al.
Publicado: (2021)

Case report: Immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma
por: Kloker, Linus D., et al.
Publicado: (2022)

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape
por: Park, Daniel H., et al.
Publicado: (2023)

Simultaneous Multiple Interaction T-cell Engaging (SMITE) Bispecific Antibodies Overcome Bispecific T-cell Engager (BiTE) Resistance Via CD28 Co-Stimulation
por: Correnti, Colin E., et al.
Publicado: (2018)

Immunological Effects and Viral Gene Expression Determine the Efficacy of Oncolytic Measles Vaccines Encoding IL-12 or IL-15 Agonists
por: Backhaus, Paul S., et al.
Publicado: (2019)

Enhanced lysis by bispecific oncolytic measles viruses simultaneously using HER2/neu or EpCAM as target receptors
por: Hanauer, Jan RH, et al.
Publicado: (2016)

Therapeutic Bispecific T-Cell Engager Antibody Targeting the Transferrin Receptor
por: Fu, Mingpeng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2q3ovk7qf8ag1sghhdq2gj37e2